Astellas Pharma has agreed to co-develop and co-commercialize Vir Biotechnology’s most advanced immuno-oncology asset, the prostate cancer candidate VIR-5500, through a collaboration that could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results